Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
Table 1
Lipid-lowering medications in the 9950 coronary artery disease patients.
Lipid-lowering medications
Patients
Total number of patients
9950
Statin monotherapy
5885 (59%)
High potency
1692 (17%)
Moderate potency
2398 (24%)
Low potency
1795 (18%)
Combination
2730 (27%)
Statin plus ezetimibe
1378 (14%)
Statin plus niacin
866 (9%)
Statin plus fibrate
650 (7%)
Statin plus fish oil
69 (<1%)
Statin plus bile acid sequestrant
43 (<1%)
No statin
1335 (13%)
No statin but other lipid lowering
389 (4%)
Ezetimibe
179 (2%)
Niacin
113 (1%)
Fibrate
170 (2%)
Fish oil
11 (<1%)
Bile acid sequestrant
37 (<1%)
No lipid-lowering therapy
946 (10%)
*Among patients on a statin plus another lipid-lowering medication, 276 patients were on more than one non-statin lipid-lowering drug.
†Among patients on no statin but another lipid-lowering medication, 121 patients were on more than one non-statin lipid-lowering drug.